R&I: Non-Small Cell Lung Cancer Market - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2020

1
Non-Small Cell Lung Cancer Market to 2020 New
Therapies to Enhance Treatment Segmentation and
Drive Growth in an Increasingly Competitive Market
Published on July 2014 No. of Pages 143
Reports and Intelligence
2
Description
GBI Research, a leading business intelligence
provider, has released its latest research
report, Non-Small Cell Lung Cancer Market to
2020 - New Therapies to Enhance Treatment
Segmentation and Drive Growth in an Increasingly
Competitive Market. The value of the Non-Small
Cell Lung Cancer (NSCLC) market is expected to
increase significantly over the forecast period
across the leading eight developed nations, from
5.1 billion in 2013 to 7.9 billion in 2020.
This equates to a Compound Annual Growth Rate
(CAGR) of 6.6. Growth will be driven by novel
therapies entering the squamous cell carcinoma
market segment, which is currently lacking
effective treatment, unlike the non-squamous
market segment. The report focuses on the
increasing differentiation between the three main
NSCLC subtypes squamous cell, adenocarcinoma,
and large cell carcinoma. Common genetic and
molecular aberrations within these histologies
are being extensively researched and targeted by
novel therapeutics and so the treatment algorithm
between histological subtypes is forecast to
become more differentiated over the forecast
period. Most notably, patients with squamous cell
carcinoma are set to benefit from crucial first-
and second-line therapies in the form of Yervoy
(ipilimumab) and nivolumab, having relied on
generic chemotherapy for the past decade. 
3
Table Of Content

• Introduction 
• Marketed Products
• NSCLC Pipeline
• Market Forecast
• Strategic Consolidations
• Appendix 
• Get full access to TOC at http//www.reportsandin
  telligence.com/non-small-cell-lung-cancer-to-2020-
  new-therapies-to-enhance-treatment-segmentation-an
  d-drive-growth-in-an-increasingly-competitive-mark
  et/table-of-contents

4
Scope

• A disease introduction, which defines the disease
  and looks at symptoms, diagnosis and treatment
• Analysis of the NSCLC marketed landscape,
  including a comparison of the efficacy and safety
  of the most prominent brands, as well as the
  unmet needs of NSCLC treatment
• Detailed analysis of the NSCLC pipeline, covering
  among other parameters, drug distribution by
  Phase, molecule type and mechanism of action. The
  NSCLC clinical trial landscape is analyzed with
  particular emphasis on failure rates across
  different trial Phases, as well as the trends in
  clinical trial size, duration and primary
  endpoint. This section also includes profiles and
  single product forecasts for the most promising
  pipeline drugs.
• An epidemiological forecast of the major NSCLC
  markets, in which projected values include total
  and treated populations
• An overview of the drivers of and barriers to the
  NSCLC market

5
Reasons To Buy

• Understand the NSCLC pipeline and the clinical
  needs that it is addressing, particularly the
  ways in which histology affects treatment options
  and where in the treatment algorithm new products
  will be positioned, as well as where unmet needs
  remain
• Develop their knowledge of key products that may
  enter the market before 2020. Detailed profiles
  of these products are provided, with a focus on
  their clinical trial performance, as well as how
  they can be incorporated into the NSCLC treatment
  plan and what competition they face.
• Assess the risk associated with NSCLC product
  development profiled by molecule type and
  mechanism of action and compared with both
  industry and therapy-area averages. In addition,
  data analyses offer a more detailed understanding
  of the trends in both trial size and duration for
  specific mechanisms of action or molecule types.
  The primary endpoint analysis infers trends in
  trial design within the therapy area, as well as
  the endpoints that are the best indicators of
  success.

6
Get access to detailed information at
http//www.reportsandintelligence.com/non-small-ce
ll-lung-cancer-to-2020-new-therapies-to-enhance-tr
eatment-segmentation-and-drive-growth-in-an-increa
singly-competitive-market Request for Discount
at http//www.reportsandintelligence.com/purchas
e-enquiry/132454